MorphoSys and Sigma-Aldrich Enter into Collaboration and Licensing Agreement for Recombinant Research Antibodies
News Feb 28, 2008
MorphoSys's AbD Serotec unit will develop and qualify antibodies from MorphoSys's proprietary HuCAL GOLD library against a committed number of targets identified and supplied by Sigma-Aldrich. HuCAL GOLD is the powerful phage-display library developed for the in vitro generation of highly specific and fully human antibodies.
The large diversity of the library guarantees fast and successful generation of high-quality antibodies to targets that have previously been difficult to probe with standard antibody-generation technologies.
Sigma-Aldrich will offer the HuCAL-based recombinant research antibodies for use in research applications through its online sales platforms Antibody Explorer™ and Your Favorite Gene Search™.
"We are very excited about the potential of this partnership," said Dr. David Smoller, president of Sigma-Aldrich's Research Biotech business unit. "HuCAL-based recombinant antibody technology will allow researchers access to antibody content not available through standard antibody generation technologies. In conjunction with Sigma-Aldrich's standard content generation capabilities, this powerful technology is expected to allow the community to reach its goal of a binder for every gene and one-day even protein in the human body."
"Non-Gene" Mutations May Hold Answers to Neurodevelopmental DisordersNews
Mutations in non-coding regions of the genome, which don't contain genes, but control the regulation of other genes, may hold answers to rare developmental disorders that affect the nervous system.READ MORE
Majority of European Wolves Have Dog DNANews
The wolf may not often act like man's best friend, but a new study has found that the majority of wild wolves in Europe contain chunks of dog DNA. The finding is causing scientists to rethink what constitutes a wolfdog hybrid and how we approach conservation of keystone wolf populations.READ MORE
Neuroblastoma Biomarker Research Advances TreatmentNews
Neuroblastoma, a childhood cancer, is treatable in less than half of aggressive cases, but new RNA biomarkers may help identify high-risk patients faster and lead to better prognosis.READ MORE